Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 H483Y |
Therapy | Letrozole + Ribociclib |
Indication/Tumor Type | Her2-receptor negative breast cancer |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 H483Y | Her2-receptor negative breast cancer | predicted - resistant | Letrozole + Ribociclib | Case Reports/Case Series | Actionable | In a clinical case study, RB1 H483Y was identified in the circulating tumor DNA of a patient with estrogen receptor (ESR1)-positive, progesterone receptor (PGR)-positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 13 months of Kisqali (ribociclib) and Femara (letrozole) combination treatment (PMID: 29236940). | 29236940 |
PubMed Id | Reference Title | Details |
---|---|---|
(29236940) | Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. | Full reference... |